Hepatitis C: The New Battleground for Access to Essential Medicines

 

Second report in the Innovation and Access to Medicines series. The report analyses the debate on access to treatment for hepatitis C, an issue that has been thrust into the international spotlight by the controversy surrounding the high cost of Sovaldi (sofosbuvir), a drug approved in late 2013.